Intrapleural paclitaxel chemotherapy in the treatment of breast cancer-related metastatic malignant pleural effusion;Korean Source

Journal of Breast Cancer

Volumn 13, Issue 4, 2010, Pages 443-447

  Park, Shin Young ^a   Choi, Jung Eun ^a   Jeon, Myung Hoon ^a   Kang, Su Hwan ^a   Lee, Soo Jung ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Malignant; Paclitaxel; Pleural effusion

Indexed keywords

ANTIBIOTIC AGENT; CAPECITABINE; CISPLATIN; CODEINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; KETOROLAC TROMETAMOL; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAMOXIFEN CITRATE; THYMOMODULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MALIGNANT PLEURAL EFFUSION; NEUTROPENIA; PARTIAL MASTECTOMY; PLEURA CANCER; PLEURA EFFUSION; PNEUMONIA; THORAX DRAINAGE; THORAX PAIN; TREATMENT DURATION; TUBE;

EID: 79251479728     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2010.13.4.443     Document Type: Article

References (14)

1. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J Surg Oncol 2004;2:16.
2. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
3. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5,255 samples from 3,811 patients. Diagn Cytopathol 1987;3:8-12.
4. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994;120:56-64.
5. Silva OE, Zurrida S. Breast Cancer: a Practical Guide. 3rd ed. New York: Elsevier Saunders; 2005.
6. Ohta Y, Shimizu Y, Matsumoto I, Watanabe G. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis. J Exp Clin Cancer Res 2006; 25:15-9.
7. Tattersall M. Pleural effusions. Curr Opin Oncol 1992;4:642-6.
8. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;138: 184-234.
9. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129:362-8.
10. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-38.
11. Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 1974;33:916-22.
12. Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer 1975;35:734-8.
13. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999;177:437-40.
14. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs 1997; 8:565-73.